- 産業: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A chemotherapy regimen consisting of chlorambucil and prednisone used for the treatment of chronic lymphocytic leukemia. (NCI Thesaurus)
Industry:Pharmaceutical
A chemotherapy regimen consisting of carboplatin and paclitaxel (Taxol) used for the treatment of endometrial, epithelial ovarian, head and neck, and advanced-stage non-small cell lung cancers. (NCI Thesaurus)
Industry:Pharmaceutical
A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.
Industry:Pharmaceutical
A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma. (NCI Thesaurus)
Industry:Pharmaceutical
A chemotherapy regimen consisting of bleomycin, etoposide and cisplatin (Platinum) used for the treatment of adult and childhood ovarian and testicular germ cell tumors. (NCI Thesaurus)
Industry:Pharmaceutical
A chemoimmunotherapy regimen consisting of carboplatin, paclitaxel (Taxol) and bevacizumab used for the treatment of advanced-stage, nonsquamous non-small cell lung cancer. (NCI Thesaurus)
Industry:Pharmaceutical
A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential immunostimulating and antineoplastic activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of AdRTVP-1-transduced prostate cancer cell-based vaccine leads to an induction of apoptosis through the expression of RTVP-1, which may result in a reduction in prostate cancer cellular proliferation. In addition, this vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor- associated antigens.
Industry:Pharmaceutical
A cell-based vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. Vaccination with GM-K562 cells may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. K562 cells are derived from the human erythroleukemia cell line K562. GM-CSF (also known as sagramostim) expressed by vaccine cells binds to specific cell surface receptors, modulating the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. GM-CSF also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
Industry:Pharmaceutical
A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.
Industry:Pharmaceutical
A cell-based vaccine composed of autologous lymphoblastoid B cells activated against Epstein-Barr virus (EBV) in vitro with potential immunoprotective activity. Upon prophylactic administration, this vaccine may stimulate specific cytotoxic T-lymphocyte (CTL) and antibody responses against EBV-transformed B cells, thereby preventing an EBV-induced post-transplantation lymphoproliferative disorder.
Industry:Pharmaceutical
